CN115572333B - 提取红汁乳菇多糖类化合物的方法 - Google Patents
提取红汁乳菇多糖类化合物的方法 Download PDFInfo
- Publication number
- CN115572333B CN115572333B CN202211286616.0A CN202211286616A CN115572333B CN 115572333 B CN115572333 B CN 115572333B CN 202211286616 A CN202211286616 A CN 202211286616A CN 115572333 B CN115572333 B CN 115572333B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- russula
- lhp
- rumex
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 156
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 156
- 241000221987 Russula Species 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 23
- -1 polysaccharide compound Chemical class 0.000 title claims abstract description 12
- 150000004676 glycans Chemical class 0.000 claims abstract description 144
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 68
- 241000219053 Rumex Species 0.000 claims abstract description 61
- 241001534110 Lactarius <percoid fish> Species 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 18
- 238000001556 precipitation Methods 0.000 claims abstract description 17
- 241000760198 Russula vinosa Species 0.000 claims abstract description 15
- 229920005989 resin Polymers 0.000 claims abstract description 15
- 239000011347 resin Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000002244 precipitate Substances 0.000 claims abstract description 14
- 238000000746 purification Methods 0.000 claims abstract description 9
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 238000005238 degreasing Methods 0.000 claims abstract description 6
- 230000001376 precipitating effect Effects 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 37
- 235000019441 ethanol Nutrition 0.000 claims description 29
- 238000000502 dialysis Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000003809 water extraction Methods 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 108090000526 Papain Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 150000003333 secondary alcohols Chemical class 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 238000012805 post-processing Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 241001411236 Rumex rupestris Species 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000011987 methylation Effects 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000005100 correlation spectroscopy Methods 0.000 description 6
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 6
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001878 scanning electron micrograph Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 241000222485 Agaricales Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001534813 Hypsizygus Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102100020859 La-related protein 1 Human genes 0.000 description 1
- 241001019498 Lactarius hatsudake Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000221986 Russulaceae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 108010041723 like heterochromatin protein 1 Proteins 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请提供一种提取红汁乳菇多糖类化合物的方法,涉及活性物质提取领域。该方法:将红汁乳菇子实体依次进行冻干、粉碎、脱脂、水提取、除蛋白、醇沉和树脂吸附得到红汁乳菇精多糖混合物;向红汁乳菇精多糖混合物内逐滴加入无水乙醇进行醇沉纯化,并逐步收集沉淀物,得到红汁乳菇多糖‑10/40/60/80活性成分;将所述红汁乳菇多糖‑10/40/60/80活性成分分别进行液相色谱制备,然后透析、后处理得到红汁乳菇多糖LHP‑1、红汁乳菇多糖LHP‑2、红汁乳菇多糖LHP‑3、红汁乳菇多糖LHP‑4、红汁乳菇多糖LHP‑5。本申请提供的提取红汁乳菇多糖类化合物的方法,首次从红汁乳菇子实体中提取得到5种多糖类化合物。
Description
技术领域
本申请涉及活性物质提取领域,尤其涉及一种提取红汁乳菇多糖类化合物的方法。
背景技术
红汁乳菇(Lactarius hatsudake Tanaka)隶属担子菌亚门、层菌纲、伞菌目、红菇科、乳菇属,主要分布在东亚地区。其营养丰富,是一种可食用和药用的珍贵食用菌。
据研究表明,红汁乳菇中含有大量的有效成分,例如氨基酸、维生素和糖类。
从红汁乳菇中分离出新的有效成分并对其进行研究,对于深度开发红汁乳菇具有十分重要的意义。
发明内容
本申请的目的在于提供一种提取红汁乳菇多糖类化合物的方法,以解决上述问题。
为实现以上目的,本申请采用以下技术方案:
一种提取红汁乳菇多糖类化合物的方法,包括:
将红汁乳菇子实体依次进行冻干、粉碎、脱脂、水提取、除蛋白、醇沉和树脂吸附得到红汁乳菇精多糖混合物;
向所述红汁乳菇精多糖混合物内逐滴加入无水乙醇进行醇沉纯化,并逐步收集乙醇体积浓度为10%、40%、60%、80%的沉淀物,得到红汁乳菇多糖-10/40/60/80活性成分;
将所述红汁乳菇多糖-10/40/60/80活性成分分别进行液相色谱制备,然后透析、后处理得到红汁乳菇多糖LHP-1、红汁乳菇多糖LHP-2、红汁乳菇多糖LHP-3、红汁乳菇多糖LHP-4、红汁乳菇多糖LHP-5;
所述液相色谱制备的条件包括:进样量1mL,色谱柱为SUGAR-BRT-102凝胶色谱柱,柱温35℃,柱长28cm,流速1.3mL/min,流动相为0.2mol/L氯化钠水溶液;
所述红汁乳菇多糖LHP-1的结构式为:
所述红汁乳菇多糖LHP-2的结构式为:
所述红汁乳菇多糖LHP-3的结构式为:
所述红汁乳菇多糖LHP-4的结构式为:
所述红汁乳菇多糖LHP-5的结构式为:
优选地,所述的方法满足以下条件中的至少一个:
a.所述冻干的温度为-80℃,时间为2-3d;
b.所述粉碎得到的颗粒物的粒径小于等于60目;
c.所述脱脂包括:使用无水乙醇反复浸泡所述粉碎得到的颗粒物,固液分离后收集固体物,干燥后再次粉碎,过60目筛得到预处理红汁乳菇冻干粉;
d.所述水提取包括:将所述脱脂后的固体物和水混合,在85℃-100℃条件下处理3h,固液分离后将固体物重复进行前述操作,合并液体得到粗多糖水溶液,浓缩得到浓缩粗多糖水溶液。
优选地,所述除蛋白包括:将所述水提取得到的溶液用木瓜蛋白酶和sevage试剂进行处理,液体放入8000-14000Da透析袋于4℃静置2-3天,期间2h换一次水,透析后浓缩得到除蛋白浓缩液。
优选地,所述醇沉包括:向所述除蛋白得到的溶液中逐滴加入4倍体积的乙醇,静置、离心得到多糖沉淀物,加水复溶后减压浓缩,冻干得到红汁乳菇次多糖。
优选地,所述树脂吸附包括:将所述醇沉得到的固体物溶于水中,然后加入活化后的JK008大孔树脂,搅拌吸附6-12h,固液分离后液体离心去除不溶物,减压蒸馏、二次醇沉、冻干得到所述红汁乳菇精多糖混合物。
优选地,进行所述醇沉纯化的过程中,每一浓度梯度滴加结束后在4℃条件下静置12h,离心得到所述沉淀物。
优选地,所述沉淀物加水复溶后减压浓缩、冻干得到所述红汁乳菇多糖-10/40/60/80活性成分。
优选地,进行所述液相色谱制备之前还包括:
将所述红汁乳菇多糖-10/40/60/80活性成分分别以水混合,60℃水浴30min,随后涡旋,过0.45μm水膜,得到相应样品。
优选地,所述透析包括:使用7000Da透析袋透析2d。
优选地,所述后处理包括:将所述透析之后得到的多糖溶液进行旋蒸、冻干,得到相应的化合物。
与现有技术相比,本申请的有益效果包括:
本申请提供的提取红汁乳菇多糖类化合物的方法,以红汁乳菇子实体为原料,进行冻干(除水分)、粉碎(提高提取率)、预处理(除去色素、小分子物质等杂质)、水提取(得到水溶性粗多糖)、除蛋白、醇沉(除去色素、小分子物质等杂质)和树脂吸附(除杂)得到红汁乳菇精多糖混合物,然后进行醇沉纯化得到4个部分的活性成分,最后进行液相色谱制备(依据分子量分级,得到单一组分)、透析(除盐)、后处理得到目标化合物。
本申请使用该方法首次从红汁乳菇子实体中提取得到红汁乳菇多糖LHP-1、红汁乳菇多糖LHP-2、红汁乳菇多糖LHP-3、红汁乳菇多糖LHP-4、红汁乳菇多糖LHP-5,前述化合物具有很好的抗肿瘤作用。
从红汁乳菇冻干粉得到红汁乳菇多糖混合物的得率为4.7%,纯度为85-91%;最终得到的LHP1/2/3/4/5的得率分别为:0.13%,1.41%,0.24%,0.564%,0.17%。
附图说明
为了更清楚地说明本申请实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本申请的某些实施例,因此不应被看作是对本申请范围的限定。
图1为实施例1进行液相制备的曲线;
图2为分子量测试曲线;
图3为红汁乳菇多糖LHP-1的扫描电子显微镜照片;
图4为红汁乳菇多糖LHP-2的扫描电子显微镜照片;
图5为红汁乳菇多糖LHP-3的扫描电子显微镜照片;
图6为红汁乳菇多糖LHP-4的扫描电子显微镜照片;
图7为红汁乳菇多糖LHP-5的扫描电子显微镜照片;
图8为红汁乳菇多糖LHP-1/2/3/4/5的红外光谱图;
图9为标准品洗脱曲线;
图10为红汁乳菇多糖LHP-1/2/3/4/5样品扫描曲线;
图11为红汁乳菇多糖LHP-1的1H NMR谱图;
图12为红汁乳菇多糖LHP-1的13C NMR谱图;
图13为红汁乳菇多糖LHP-1的1H 1H COSY谱图;
图14为红汁乳菇多糖LHP-1的HMBC谱图;
图15为红汁乳菇多糖LHP-1的HSQC谱图;
图16为红汁乳菇多糖LHP-2的1H NMR谱图;
图17为红汁乳菇多糖LHP-2的13C NMR谱图;
图18为红汁乳菇多糖LHP-2的1H 1H COSY谱图;
图19为红汁乳菇多糖LHP-2的HMBC谱图;
图20为红汁乳菇多糖LHP-2的HSQC谱图;
图21为红汁乳菇多糖LHP-3的1H NMR谱图;
图22为红汁乳菇多糖LHP-3的13C NMR谱图;
图23为红汁乳菇多糖LHP-3的1H 1H COSY谱图;
图24为红汁乳菇多糖LHP-3的HMBC谱图;
图25为红汁乳菇多糖LHP-3的HSQC谱图;
图26为红汁乳菇多糖LHP-4的1H NMR谱图;
图27为红汁乳菇多糖LHP-4的13C NMR谱图;
图28为红汁乳菇多糖LHP-4的1H 1H COSY谱图;
图29为红汁乳菇多糖LHP-4的HMBC谱图;
图30为红汁乳菇多糖LHP-4的HSQC谱图;
图31为红汁乳菇多糖LHP-5的1H NMR谱图;
图32为红汁乳菇多糖LHP-5的13C NMR谱图;
图33为红汁乳菇多糖LHP-5的1H 1H COSY谱图;
图34为红汁乳菇多糖LHP-5的HMBC谱图;
图35为红汁乳菇多糖LHP-5的HSQC谱图;
图36为红汁乳菇多糖混合物抑制HepG2荷瘤小鼠肿瘤增长实验小鼠肿瘤体积变化照片;
图37为红汁乳菇多糖混合物抑制HepG2荷瘤小鼠肿瘤增长实验小鼠脏器照片;
图38为细胞存活率柱状图。
具体实施方式
下面将结合具体实施例对本申请的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本申请,而不应视为限制本申请的范围。
实施例1
本实施例提供一种提取红汁乳菇多糖类化合物的方法,具体包括以下步骤:
(1)红汁乳菇多糖混合物的制备:
冻干:取红汁乳菇子实体擦净、去蒂,于冻干机干燥2天。
粉碎:取冻干的红汁乳菇子实体粉碎,过60目筛,得到红汁乳菇冻干粉。
脱脂:取300g红汁乳菇粉于5000mL烧杯中,加入3000mL无水乙醇,室温下静置12h,抽滤,上清液60℃减压浓缩回收乙醇,滤饼继续重复此操作共3次,最后收集滤饼,冷风烘干,烘干后的滤饼用粉碎机粉碎,过60目筛,得到预处理红汁乳菇冻干粉。
水提:取300g预处理红汁乳菇冻干粉于反应釜,加入6000mL超纯水,于85℃条件下水浴搅拌3h,将混合液先用纱布过滤分离滤渣和水溶液,得到的水溶液进一步5000rap离心15min,收集滤渣重复上述操作,收集两次上清液合并为粗多糖水溶液,减压浓缩至1500mL。
除蛋白:将浓缩后粗多糖水溶液中,加入3g木瓜蛋白酶,60℃下反应1h,反应结束后,将温度上升到100℃灭活10min,10000rap离心20min除去蛋白质,收集上清液,加入1/4体积的sevage试剂(氯仿:正丁醇=4:1),磁力搅拌反应20min后10000rap离心20min,取上层水相,除去中间蛋白质沉淀以及下层有机相,此操作重复5次直到无蛋白质沉淀。多糖水溶液于60℃减压浓缩除去有机相反复加水旋蒸,直到体系无有机,收集的上清液放入14000Da透析袋于4℃静置2天,期间2h换一次水,透析后的溶液减压浓缩至600mL。
醇沉:将上述水提浓缩液加入4倍体积的乙醇,用分液漏斗调速至逐滴落下,同时利用磁力搅拌保证每滴乙醇均匀散落到整个溶液体系,于4℃条件下静置12h,10000rap离心10min,将多糖沉淀物加水复溶,60℃减压浓缩除去乙醇,浓缩液冻干得红汁乳菇次多糖。
树脂吸附:取30mg红汁乳菇次多糖溶于3000mL超纯水,加入500g活化好的JK008大孔树脂,搅拌吸附6h,用纱布过滤分离树脂和多糖水溶液,10000rap离心20min除去不溶物,60℃减压浓缩、醇沉、冻干,得到红汁乳菇多糖混合物。
(2)红汁乳菇多糖-1/2/3/4/5的制备:
醇沉纯化:取1g红汁乳菇多糖混合物溶于200mL超纯水,逐滴加入无水乙醇至体系为10%浓度,于4℃静置12h,离心得到红汁乳菇多糖-10沉淀,收集上清液继续加入无水乙醇至体系为40%浓度,于4℃静置12h,离心得到红汁乳菇多糖-40沉淀,收集上清液继续加入无水乙醇至体系为60%浓度,于4℃静置12h,离心得到红汁乳菇多糖-60沉淀,收集上清液继续加入无水乙醇至体系为80%浓度,于4℃静置12h,离心得到红汁乳菇多糖-80沉淀。多糖复溶,减压浓缩,冻干得到红汁乳菇多糖-10/40/60/80活性成分。
制备液相纯化:取100mg红汁乳菇多糖-10/40/60/80活性成分于5mL EP管中,加入2mL超纯水,于60℃水浴30min,随后涡旋,过0.45水膜,进样量1mL,色谱柱为SUGAR-BRT-102凝胶色谱柱,检测器:岛津RID-10A示差折光检测器,流动相为0.2mol/L氯化钠水溶液,流速1.3mL/min,将收集的洗脱组分利用7000Da透析袋透析2天,透析完后的多糖溶液旋蒸、冻干得到红汁乳菇多糖LHP-1/2/3/4/5,结果如图1所示(5个化合物对应的时间依次分别为12.28、13.78、18.22、38.419、43.89min)。
为了进一步说明所得多糖化合物的结构,对红汁乳菇多糖-LHP-1/2/3/4/5的结构表征,具体如下:
(1)分子量分析:将1mg红汁乳菇多糖LHP-1/2/3/4/5与葡聚糖标准品配成0.1mg/mL溶液,采用凝胶色谱仪进行分析对红汁乳菇精多糖LHP和LHP-1/2/3/4/5的分子量进行测试。实验结果如图2,红汁乳菇多糖-LHP-1/2/3/4/5的重均分子量分别为712kDa、515kDa、303kDa、20kDa、7kDa。
(2)扫描电镜:将红汁乳菇多糖LHP-1/2/3/4/5固定在带有导电胶的铝板上,使用离子溅射涂布机在真空下喷金。通过扫描电子显微镜分析每个样品的表面形态,结果如图3、图4、图5、图6、图7所示(分别依次对应红汁乳菇多糖LHP-1/2/3/4/5)。
(3)红外光谱:取1mg红汁乳菇多糖LHP-1/2/3/4/5冻干样品,以与100mg KBr固体混合均匀,研磨成粉末,然后将粉末压入1mm厚的圆盘中压成透明压片,使用傅里叶变换红外光谱仪在4000-400cm1的频率范围内扫描,如图8所示。
(4)单糖组成:称一定量样品(2mg左右)于1.5mL EP管中,配置4mg/mL的样品溶液。取200μL样品溶液于具塞试管中,加入400μL 4M的三氟乙酸溶液混匀,于110℃油浴条件下水解2h,随后氮吹吹干,再加入400μL乙醇使其溶解。取单糖样品加超纯水配成1mg/mL溶液,备用。取上述溶液(单糖溶液或多糖水解液)100μL于2mL EP管中,分别加入100μL 0.3M的NaOH溶液和0.5M的PMP-甲醇溶液,混匀后于70℃条件下反应30min,冷却后再加入0.3M的HCl溶液,补水至1mL,再加入1mL三氯甲烷将PMP萃取出来,重复三次。将上层溶液过膜备用。
LHPLC条件:色谱柱:Sepax Bio-C18,4.6×250mm,5μm,检测器:RID-10A示差折光检测器,波长250nm,流动相:0.05M甲酸铵溶液和乙腈,比例为83:17;流速1mL/min。
标品顺序依次为甘露糖、核糖、葡萄糖醛酸、半乳糖醛酸、葡萄糖、半乳糖、木糖、阿拉伯糖、岩藻糖得到的洗脱曲线如图9,样品扫描图如图10所示。
(5)红汁乳菇多糖LHP-1/2/3/4/5甲基化分析:
称量多糖样品(2-3mg)置于玻璃反应瓶中,加入1mL无水DMSO,快速加入甲基化试剂A液,封闭,在超声作用下溶解,再加入甲基化试剂B液。在磁力搅拌水浴30℃反应60min反应。最后将2mL超纯水加入到上述混合物中终止甲基化反应。
取甲基化后的多糖,加入1mL的2M三氟乙酸(TFA)水解90min,旋转蒸发仪蒸干。残基加入2mL双蒸水,60mg硼氢化钠还原8小时,加入冰醋酸中和,旋蒸,101℃烘箱烘干,然后加入1mL乙酸酐乙酰化100℃反应1h,冷却。然后加入3mL甲苯,减压浓缩蒸干,重复4-5次,以除去多余的醋酐。
将乙酰化后的产物用3mL CH2Cl2溶解后转移至分液漏斗,加入少量蒸馏水充分震荡后,除去上层水溶液,如此重复4次。CH2Cl2层以适量的无水硫酸钠干燥,定容10mL,放入液相小瓶。分析采用Shimadzu GCMS-QP 2010气相色谱-质谱联用仪测定乙酰化产物样品;
GC-MS条件:RXI-5SIL MS色谱柱30m*0.25mm*0.25μm;程序升温条件为:起始温度120℃,以3℃/min升温至250℃/min;保持5min;进样口温度为250℃,检测器温度为250℃/min,载气为氦气,流速为1mL/min。结果如表1、表2、表3、表4、表5。
表1 LHP-1纯化组分多糖甲基化糖醇乙酰酯(PMAA)结果分析
表2 LHP-2纯化组分多糖甲基化糖醇乙酰酯(PMAA)结果分析
RT | Methylated sugar | Mass fragments(m/z) | Molar ratio | Type of linkage |
17.959 | 2,3,4-Me3-Fucp | 43,59,72,89,101,115,117,131,175 | 0.007 | Fucp-(1→ |
23.889 | 2,3,4,6-Me4-Glcp | 43,71,87,101,117,129,145,161,205 | 0.056 | Glcp-(1→ |
29.1 | 2,3,6-Me3-Galp | 43,87,99,101,113,117,129,131,161,173,233 | 0.014 | →4)-Galp-(1→ |
30.404 | 2,3,6-Me3-Glcp | 43,87,99,101,113,117,129,131,161,173,233 | 0.790 | →4)-Glcp-(1→ |
33.619 | 2,6-Me2-Glcp | 43,87,97,117,159,185 | 0.046 | →3,4)-Glcp-(1→ |
36.661 | 2,3-Me2-Glcp | 43,71,85,87,99,101,117,127,159,161,201 | 0.081 | →4,6)-Glcp-(1→ |
40.815 | 2-Me1-Glcp | 43,58,87,97,117,139 | 0.006 | →3,4,6)-Glcp-(1→ |
表3 LHP-3纯化组分多糖甲基化糖醇乙酰酯(PMAA)结果分析
表4 LHP-4纯化组分多糖甲基化糖醇乙酰酯(PMAA)结果分析
RT | Methylated sugar | Mass fragments(m/z) | Molar ratio | Type of linkage |
17.622 | 2,3,5-Me3-Xylp | 43,71,87,101,117,129,145,161 | 0.010 | Xylp-(1→ |
17.993 | 2,3,4-Me3-Fucp | 43,59,72,89,101,115,117,131,175 | 0.245 | Fucp-(1→ |
21.41 | 2,4-Me2-Xylp | 43,58,85,99,101,117,127,159,173 | 0.006 | →3)-Xylp-(1→ |
21.705 | 2,3-Me2-Xylp | 43,71,87,99,101,117,129,161,189 | 0.002 | →4)-Xylp-(1→ |
23.699 | 2,3,4,6-Me4-Glcp | 43,71,87,101,117,129,145,161,205 | 0.035 | Glcp-(1→ |
24.667 | 2,3,4,6-Me4-Galp | 43,71,87,101,117,129,145,161,205 | 0.005 | Galp-(1→ |
28.708 | 2,4,6-Me3-Glcp | 43,87,99,101,117,129,161,173,233 | 0.013 | →3)-Glcp-(1→ |
29.351 | 2,3,6-Me3-Glcp | 43,87,99,101,113,117,129,131,161,173,233 | 0.031 | →4)-Glcp-(1→ |
30.62 | 2,3,4-Me3-Glcp | 43,87,99,101,117,129,161,189,233 | 0.035 | →6-Glcp-(1→ |
32.78 | 2,3,4-Me3-Galp | 43,87,99,101,117,129,161,189,233 | 0.262 | →6)-Galp-(1→ |
33.334 | 2,6-Me2-Glcp | 43,87,97,117,159,185 | 0.003 | →3,4)-Glcp-(1→ |
36.226 | 2,3-Me2-Glcp | 43,71,85,87,99,101,117,127,159,161,201 | 0.006 | →4,6)-Glcp-(1→ |
36.699 | 2,4-Me2-Galp | 43,87,117,129,159,189,233 | 0.010 | →3,6)-Galp-(1→ |
38.702 | 3,4–Me2-Manp | 43,87,99,129,189 | 0.337 | →2,6)-Manp-(1→ |
40.686 | 2-Me1-Galp | 43,87,97,117,139,159,173,233 | 0.001 | →3,4,6)-Galp-(1→ |
表5 LHP-5纯化组分多糖甲基化糖醇乙酰酯(PMAA)结果分析
(6)核磁共振分析:取30mg红汁乳菇多糖/2/3/4/5溶于1mL重水中,放入5mL的试管。将溶液移入核磁管,采用脉冲傅里叶变换谱仪,对样品进行扫描。得到的LHP-1的1HNMR、13C NMR、1H 1H COSY、HMBC、HSQC谱图见图11、图12、图13、图14、图15;LHP-2的谱图见图16、图17、图18、图19、图20;LHP-3的谱图见图21、图22、图23、图24、图25;LHP-4的谱图见图26、图27、图28、图29、图30;LHP-5的谱图见图31、图32、图33、图34、图35。由图可知,红汁乳菇多糖LHP-1/2/3/4/5的各个糖残基的13C、1H的化学位移如表6、表7、表8、表9、表10所示,与甲基化结构符合。
表6红汁乳菇多糖LHP-1糖残基的13C、1H的化学位移
表7红汁乳菇多糖LHP-2糖残基的13C、1H的化学位移
表8红汁乳菇多糖LHP-3糖残基的13C、1H的化学位移
表9红汁乳菇多糖LHP-4糖残基的13C、1H的化学位移
表10红汁乳菇多糖LHP-5糖残基的13C、1H的化学位移
经过以上对红汁乳菇多糖LHP-1/2/3/4/5的结构表征,解析如下:
LHP-1组分的1H和13C NMR谱图,在异头质子(4.3-5.2ppm)和异头碳(90-110ppm)区域有6个主峰,结合甲基化和单糖组成结果,将信号强较的5.32/99.72、4.93/100.11和5.04/98.47分别归属于→4)-α-Glcp-(1→、→4,6)-α-Glcp-(1→和→α-Fucp-(1→,剩下的弱信号将4.93/98.02、5.28/100.11和5.15/91.87归属于→6)-α-Galp-(1→、α-Glcp-(1→和→3,4,6)-α-Glcp-(1→。再依据HSQC和13C找出对应质子的共振峰。HMBC图所示,交叉峰5.32/71.07和3.50/99.72说明→4)-α-Glcp-(1→的H-1和C-4以及C-1的H-4有偶联关系,交叉峰3.61/99.72说明→4)-α-Glcp-(1→的C-1和→4,6)-α-Glcp-(1→的H4有偶联关系,作为此组分的主链。除此之外,交叉峰5.04/71.06说明→α-Fucp-(1→的H-1和→4,6)-α-Glcp-(1→的C-6有偶联关系。交叉峰4.93/70.43和4.93/71.06说明→6)-α-Galp-(1→的H1和→4,6)-α-Glcp-(1→和→6)-α-Galp-(1→的C-6偶联。
综合上述结果,红汁乳菇多糖LHP-1的结构式为:
LHP-2组分的1H和13C NMR谱图,在异头质子(4.3-5.2ppm)和异头碳(90-110ppm)区域有6个主峰,结合甲基化和单糖组成结果,将信号强较的5.32/101.07、5.29/101.45和4.90/100.03分别归属于→4)-α-Glcp-(1→、Glcp-(1→和→4,6)-α-Glcp-(1→,剩下的弱信号将5.15/93.35、5.15/93.35和4.57/97.28归属于→3,4)-α-Glcp-(1→、→3,4,6)-α-Glcp-(1→和→4)-β-Galp-(1→。再依据HSQC和13C找出对应质子的共振峰。HMBC图谱交叉峰5.32/73.02、5.32/76.60、5.32/72.02、5.32/78.35说明→4)-α-Glcp-(1→的H-1和→4)-α-Glcp-(1→、→4,6)-α-Glcp-(1→、→3,4)-α-Glcp-(1→的C-4以及→3,4,6)-α-Glcp-(1→的C-3偶联,交叉峰5.29/72.01表明Glcp-(1→的H-1和→4,6)-α-Glcp-(1→的C-6偶联,交叉峰4.57/76.33表明→4)-β-Galp-(1→的H-1和→3,4)-α-Glcp-(1→的C-3偶联。
综合上述结果,红汁乳菇多糖LHP-2的结构式为:
LHP-3组分的1H和13C NMR谱图,在异头质子(4.3-5.2ppm)和异头碳(90-110ppm)区域有6个主峰,结合甲基化和单糖组成结果,将信号强较的4.89/99.39、4.89/101.50和5.00/99.783分别归属于→6)-α-Galp-(1→、→2,6)-α-Manp-(1→和→α-Fucp-(1→,剩下的弱信号将5.29/101.05、4.84/101.05和5.27/101.26归属于→4)-α-Glcp-(1→、→3)-α-Glcp-(1→和α-Glcp-(1→。再依据HSQC和13C找出对应质子的共振峰。HMBC图谱交叉峰4.89/71.14、4.89/78.36说明→6)-α-Galp-(1→的H-1和→6)-α-Galp-(1→的C-6以及→2,6)-α-Manp-(1→的C-6偶联,交叉峰5.00/70.36表明→α-Fucp-(1→的H-1和→2,6)-α-Manp-(1→的C-2偶联,交叉峰4.84/70.36表明→3)-α-Glcp-(1→的H-1和→2,6)-α-Manp-(1→的C-2偶联。
综合上述结果,红汁乳菇多糖LHP-3的结构式为:
LHP-4组分的1H和13C NMR谱图,在异头质子(4.3-5.2ppm)和异头碳(90-110ppm)区域有7个主峰,结合甲基化和单糖组成结果,将信号强较的4.88/99.34、4.88/101.4和4.99/100.10分别归属于→6)-α-Galp-(1→、→2,6)-α-Manp-(1→和α-Fucp-(1→,剩下的弱信号将5.27/101.01、4.82/101.00、5.24/101.13和4.41/104.41归属于→4)-α-Glcp-(1→、→3)-α-Glcp-(1→、α-Glcp-(1→和→6)-β-Glcp-(1→。再依据HSQC和13C找出对应质子的共振峰。HMBC图谱交叉峰4.88/78.28、4.88/71.27说明→6)-α-Galp-(1→的H-1和→6)-α-Galp-(1→的C-6以及→2,6)-α-Manp-(1→的C-6偶联,交叉峰4.89/78.28表明α-Fucp-(1→的H-1和→2,6)-α-Manp-(1→的C-2偶联,交叉峰3.86/101.01、3.86/100.00、3.86/101.03表明→2,6)-α-Manp-(1→的H-2和→4)-α-Glcp-(1→、→3)-α-Glcp-(1→和α-Glcp-(1→的C-1偶联,交叉峰3.38/104.41说明→4)-α-Glcp-(1→的H-4和→6)-β-Glcp-(1→的C-1偶联。
综合上述结果,红汁乳菇多糖LHP-4的结构式为:
LHP-5组分的1H和13C NMR谱图,在异头质子(4.3-5.2ppm)和异头碳(90-110ppm)区域有8个主峰,结合甲基化和单糖组成结果,将信号强较的4.62/104.15、4.44/104和5.15/93.11分别归属于→3)-α-Glcp-(1→、→6)-β-Glcp-(1→和→3,6)-β-Glcp-(1→,剩下的弱信号将4.92/99.23、4.92/101.3和5.26/101.63、5.31/100.89和5.03/99.58归属于→2,6)-α-Manp-(1→、→6)-α-Galp-(1→、α-Glcp-(1→、→4)-α-Glcp-(1→和α-Fucp-(1→。再依据HSQC和13C找出对应质子的共振峰。HMBC图谱交叉峰4.62/85.23说明→3)-α-Glcp-(1→的H-1和→3)-α-Glcp-(1→以及→3,6)-β-Glcp-(1→的C-3偶联,交叉峰3.36/100.40和3.67/100.40表明→6)-β-Glcp-(1→的C-1和→3,6)-β-Glcp-(1→以及→2,6)-α-Manp-(1→的H-6偶联,交叉峰5.03/71.38和4.92/71.38说明→2,6)-α-Manp-(1→的C-2和→6)-α-Galp-(1→以及Fucp-(1→的H-1相连。
综合上述结果,红汁乳菇多糖LHP-5的结构式为:
为了研究所得到的红汁乳菇多糖混合物和红汁乳菇多糖LHP-1/2/3/4/5的相关作用,特进行如下试验:
1.红汁乳菇多糖混合物LHP抑制HepG2荷瘤小鼠肿瘤增长实验
选取雄性BALB/C裸鼠(4~5周龄)(SPF级),维持在标准条件下(25±2℃,60±5%的湿度,12h光/暗循环),自由获得食物和水。小鼠适应一周后开始造模。液氮中取出HepG2细胞冻存管,迅速置于37℃水浴并轻轻摇动,使迅速完全解冻。超净台内用75%酒精擦拭冻存管外表面,无菌操作,除去封口膜,打开管盖,吸管吸出细胞悬液,置于15mL BD离心管中,补加生理盐水至10mL左右,吸管轻轻吹打均匀悬浮细胞,800r/min离心10min,弃上清。再重复上述洗涤过程两次,适量生理盐水均匀悬浮细胞,计数,每只小鼠注射1×107个/只,0.2mL/只无菌条件下接种于小鼠腹腔内,至肿瘤体积至100mm3,则造模成功。实验分为3组,模型组灌胃生理盐水,多糖干预组(剂量分别为250、500mg/kg),每组5只小鼠。实验前称取每只小鼠体重,实验期间正常饮食并测量体重和肿瘤体积,如表11、图36,与对照组相比,肿瘤体积明显减小。实验组灌胃对应剂量多糖样品,17天后解剖,摘取肝脏、脾脏、胸腺、结肠等脏器如表12、图37,与对照组相比,肝脏病理情况减少,脾腺减小。
表11多糖对HepG2荷瘤小鼠肿瘤体积的影响(x±s,n=5)
注:与模型对照组比较,*P≤0.05,**P≤0.01。
表12多糖对HepG2荷瘤小鼠肿瘤肿瘤、肝脏、脾脏脏体比的影响
组别 | 瘤体比(%) | 肝体比(%) | 脾体比(%) |
模型对照组 | 3.123±0.887 | 6.541±0.630 | 0.879±0.083 |
多糖干预低剂量组 | 2.398±0.892 | 6.382±0.541 | 0.629±0.221* |
多糖干预高剂量组 | 1.298±0.854* | 6.670±0.170 | 0.715±0.044 |
注:与模型对照组比较,*P≤0.05;x±s,n=5。
2.红汁乳菇多糖LHP-1/2/3/4/5抑制癌细胞增长实验
红汁乳菇精多糖LHP和LHP-1/2/3/4/5对HepG2细胞的实验过程:
细胞增殖实验:将HepG2细胞复苏后,置于含有10%PBS的DMEM/1640培养基中培养,并置于37℃、5%CO2条件的培养箱中。当HepG2细胞长满细胞培养皿底部时,加入1mL胰酶,细胞消化完成后吸去胰酶,向培养基中加入培基后,吹打,使用血球计数板计数,并按70~80%左右吸出原培养基,向96孔板中分别加入100μL含红汁乳菇多糖LHP-1/2/3/4/5浓度为0、25、50、100、200、400μg/mL的DMEM培养基,37℃孵育24h。再向各孔加入10μL的MTS试剂,孵育30min。使用酶标仪测490nm处的吸光度。计算细胞存活率,结果如图38所示(图内每组柱状图中从左至右依次为LHP-1/2/3/4/5)。
实施例2
与实施例1不同的是,水提温度为90℃,除蛋白过程中透析时间为3天,JK008大孔树脂吸附时间为10h。
实施例3
与实施例1不同的是,水提温度为100℃,JK008大孔树脂吸附时间为12h。
对比例1
多糖纯化部分,树脂选择JK008,纯度为85~90%,前期使用树脂D941得到的纯度仅73%。
乙醇分级时,多糖的浓度为5mg/mL,浓度过高,10%部分为坚硬胶状,无法分离。
对比例2
与实施例1不同的是,步骤(2)中醇沉纯化时,仅使用40%、60%和80%无水乙醇体系进行。
在该体系下,由于缺少10%浓度的处理,40%组分呈胶状,且凝胶色谱柱配合液相扫描图为多峰的复杂物,无法像实施例1的40%组分峰形单一,最后无法得到LHP-2组分。
对比例3
与实施例1不同的是,步骤(2)中醇沉纯化时,仅使用30%、40%、50%、60%和70%无水乙醇体系进行。
在该体系下,发现30%组分几乎占精多糖的80-90%,且组成复杂,均一性差,导致后面的4个组分量极少,整个多糖分离效果差,无法进行下一步分制备液相离。
分析醇沉体系可以发现,10%、40%、60%、80%体系的建立对于5个目标化合物的分离至关重要,同时也极大程度的影响着他们的纯度。其中,10%浓度无水乙醇的使用,是后续40%、60%、80%醇沉产物能够有效分离的关键。
最后应说明的是:以上各实施例仅用以说明本申请的技术方案,而非对其限制;尽管参照前述各实施例对本申请进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本申请各实施例技术方案的范围。
Claims (9)
1.一种提取红汁乳菇多糖类化合物的方法,其特征在于,包括:
将红汁乳菇子实体依次进行冻干、粉碎、脱脂、水提取、除蛋白、醇沉和树脂吸附得到红汁乳菇精多糖混合物;所述树脂吸附包括:将所述醇沉得到的固体物溶于水中,然后加入活化后的JK008大孔树脂,搅拌吸附6-12 h,固液分离后液体离心去除不溶物,减压蒸馏、二次醇沉、冻干得到所述红汁乳菇精多糖混合物;
向所述红汁乳菇精多糖混合物内逐滴加入无水乙醇进行醇沉纯化,并逐步收集乙醇体积浓度为10%、40%、60%、80%的沉淀物,得到红汁乳菇多糖-10/40/60/80活性成分;所述红汁乳菇精多糖混合物的浓度小于5mg/ml;
将所述红汁乳菇多糖-10/40/60/80活性成分分别进行液相色谱制备,然后透析、后处理得到红汁乳菇多糖LHP-1、红汁乳菇多糖LHP-2、红汁乳菇多糖LHP-3、红汁乳菇多糖LHP-4、红汁乳菇多糖LHP-5;
所述液相色谱制备的条件包括:进样量1 mL,色谱柱为SUGAR-BRT-102凝胶色谱柱,柱温35℃,柱长28cm,流速1.3 mL/min,流动相为0.2 mol/L氯化钠水溶液;
所述红汁乳菇多糖LHP-1的结构式为:
所述红汁乳菇多糖LHP-2的结构式为:
所述红汁乳菇多糖LHP-3的结构式为:
所述红汁乳菇多糖LHP-4的结构式为:
所述红汁乳菇多糖LHP-5的结构式为:
2.根据权利要求1所述的方法,其特征在于,满足以下条件中的至少一个:
a.所述冻干的温度为-80℃,时间为2-3 d;
b.所述粉碎得到的颗粒物的粒径小于等于60目;
c.所述脱脂包括:使用无水乙醇反复浸泡所述粉碎得到的颗粒物,固液分离后收集固体物,干燥后再次粉碎,过60目筛得到预处理红汁乳菇冻干粉;
d.所述水提取包括:将所述脱脂后的固体物和水混合,在85℃-100℃条件下处理3 h,固液分离后将固体物重复进行前述操作,合并液体得到粗多糖水溶液,浓缩得到浓缩粗多糖水溶液。
3.根据权利要求1所述的方法,其特征在于,所述除蛋白包括:将所述水提取得到的溶液用木瓜蛋白酶和sevage试剂进行处理,液体放入8000-14000 Da透析袋于4℃静置2-3天,期间2 h换一次水,透析后浓缩得到除蛋白浓缩液。
4.根据权利要求1所述的方法,其特征在于,所述醇沉包括:向所述除蛋白得到的溶液中逐滴加入4倍体积的乙醇,静置、离心得到多糖沉淀物,加水复溶后减压浓缩,冻干得到红汁乳菇次多糖。
5.根据权利要求1所述的方法,其特征在于,进行所述醇沉纯化的过程中,每一浓度梯度滴加结束后在4℃条件下静置12 h,离心得到所述沉淀物。
6.根据权利要求5所述的方法,其特征在于,所述沉淀物加水复溶后减压浓缩、冻干得到所述红汁乳菇多糖-10/40/60/80活性成分。
7.根据权利要求1所述的方法,其特征在于,进行所述液相色谱制备之前还包括:
将所述红汁乳菇多糖-10/40/60/80活性成分分别以水混合,60℃水浴30 min,随后涡旋,过0.45 μm水膜,得到相应样品。
8.根据权利要求1所述的方法,其特征在于,所述透析包括:使用7000 Da透析袋透析2d。
9.根据权利要求1-8任一项所述的方法,其特征在于,所述后处理包括:将所述透析之后得到的多糖溶液进行旋蒸、冻干,得到相应的化合物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211286616.0A CN115572333B (zh) | 2022-10-20 | 2022-10-20 | 提取红汁乳菇多糖类化合物的方法 |
US18/454,333 US20240156855A1 (en) | 2022-10-20 | 2023-08-23 | Method for extracting lactarius hatsudake tanaka polysaccharide compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211286616.0A CN115572333B (zh) | 2022-10-20 | 2022-10-20 | 提取红汁乳菇多糖类化合物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115572333A CN115572333A (zh) | 2023-01-06 |
CN115572333B true CN115572333B (zh) | 2023-06-09 |
Family
ID=84587574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211286616.0A Active CN115572333B (zh) | 2022-10-20 | 2022-10-20 | 提取红汁乳菇多糖类化合物的方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20240156855A1 (zh) |
CN (1) | CN115572333B (zh) |
-
2022
- 2022-10-20 CN CN202211286616.0A patent/CN115572333B/zh active Active
-
2023
- 2023-08-23 US US18/454,333 patent/US20240156855A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115572333A (zh) | 2023-01-06 |
US20240156855A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Structural characterization and immune activity screening of polysaccharides with different molecular weights from Astragali Radix | |
Li et al. | Screening and structure study of active components of Astragalus polysaccharide for injection based on different molecular weights | |
CN112358553B (zh) | 一种多糖sm-0.2m及其制备的抗肿瘤产品 | |
CN112812197B (zh) | 一种兰州百合多糖及其制备方法和应用 | |
CN111410699B (zh) | 西藏灵芝多糖glp-3及其制备方法与应用 | |
CN112062866B (zh) | 一种猴头菌富硒多糖及其制备方法和用途 | |
CN115572333B (zh) | 提取红汁乳菇多糖类化合物的方法 | |
CN115746156B (zh) | 一种具有免疫调节功能的枸杞多糖及其制备方法 | |
Huang et al. | Structural characterization of a novel Lactarius volemus Fr. polysaccharide and its immunity activity in BALB/c mice | |
Wang et al. | The structural characterization and anticancer activity of a polysaccharide from Coriolus versicolor | |
CN115710320A (zh) | 一种预防和/或治疗自身免疫疾病的黄精多糖 | |
CN113480674B (zh) | 一种黑茶多糖-ⅰ活性成分及其制备方法和在抗癌中应用 | |
CN112521521B (zh) | 一种多糖sm-w及其制备的抗肿瘤产品 | |
CN113817076A (zh) | 一种具有免疫调节活性的点柄乳牛肝菌多糖sgp2-1及其制备方法和应用 | |
CN114957497A (zh) | 一种滇龙胆酸性多糖及其制备方法与应用 | |
CN110204627B (zh) | 一种美网柄牛肝菌多糖及其制备方法和应用 | |
CN113105567A (zh) | 一种蝉拟青霉甘露聚糖及其制备和用途 | |
CN112778430A (zh) | 一种硫酸化修饰青钱柳多糖及其制备方法和应用 | |
Huang et al. | Characterization and in vivo immunomodulatory effects of a heteropolysaccharide from Rhizopogon rubescens (Tul.) Tul | |
CN110894244B (zh) | 一种土鳖虫多糖的结构及其用途 | |
CN116925962B (zh) | 具有肠道菌群和免疫调节功能的解淀粉芽孢杆菌jm033产胞外多糖及其应用 | |
CN114409824B (zh) | 毛霉胞外多糖及其制备方法和应用 | |
CN116425901B (zh) | 苦笋多糖及其制备方法和用途 | |
CN112759661B (zh) | 金樱子多糖制备方法、鉴定方法和应用 | |
CN115960274B (zh) | 一种覆盆子多糖及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |